Press Room

Webinar Series: All you need to know about Continuous Tableting

Start
Wednesday, May 29, 2024 - 16:00
End
Wednesday, July 10, 2024 - 17:00
Location: online
Webinar series - all you need to know about continuous tableting | Hovione

Hovione presents the most comprehensive three-part webinar series on "Opportunities, Challenges and Success in Implementing Continuous Tableting – From R&D to Commercial Manufacturing".

Over the course of this series, Hovione experts and invited speakers from Merck Sharpe & Dohme, Vertex Pharmaceuticals and GEA Group will guide you through the journey of continuous manufacturing (CM) of oral solid dosage forms, also known as continuous tableting (CT), aiming to highlight key opportunities, successes, and challenges with continuous tableting. 

The content of the webinars will cover the role of CM along a wide breadth of the CMC journey, starting with lean and model-based development and concluding with commercial implementation of continuous tableting processes. 

Each session in the series will be presented as a joint talk with participants from innovators like Merck and Vertex Pharmaceuticals, and Hovione, highlighting experiences from each organization and the many advantages of a partnership-based approach. The webinar series will conclude with a final joint talk between GEA Group and Hovione announcing exciting joint innovations in the CT equipment space along with the latest advances in technology simplification.

Featured experts will be available to answer audience questions during a live Q&A after each talk.

SESSION 1 - On-demand

Lean Process Development for Continuous Tableting: Foundations of a Hybrid Approach

The recording is now available.

SESSION 2 - On-demand

Insights from Commercial Implementation of Continuous Tableting: Successes and Challenges of a Partnership-Oriented Approach

Thursday, June 20
11:00 am EDT  |  4:00 pm GMT  |  ​5:00 pm CEST

SESSION 3 - On-demand

Simplification of Continuous Tableting for Accelerated Product Development and Lifecycle Flexibility

Wednesday, July 10
11:00 am EDT  |  4:00 pm GMT  |  5:00 pm CEST

 

 

 

 

 

 

 

 

 

 

 

Find out today if continuous tableting is right for your product. 

The Future is Continuous.

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026